Kangstem Biotech Co., Ltd. (217730.KQ) Stock
Kangstem Biotech Co., Ltd.

Company profile
Kangstem Biotech reported revenue of 3.57 billion KRW for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 805.01 million KRW. Its largest business segment, Non-Clinical Trials, brought in 55% of segment revenue in fiscal year 2023. In Q1 2026 it reported a net loss of 4.56 billion KRW. Our analysis of its filings shows revenue shrinking from 12.70 billion KRW in fiscal year 2023 to 3.57 billion KRW in fiscal year 2025, 47.0% a year on average. Kangstem Biotech reports about 100 full-time employees.
What stands out
- Revenue fell 53.9% in fiscal year 2025, from 7.75 billion KRW in fiscal year 2024, after a fall of 39.0% the year before.
- It reported a net loss in each of its last 5 fiscal years; the loss widened from 7.99 billion KRW in fiscal year 2024 to 10.48 billion KRW in fiscal year 2025.
- It spent 12.58 billion KRW on research and development in fiscal year 2025, 3.5 times its revenue.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Kangstem Biotech Co., Ltd.
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
Largest shareholders
- Hyung-Jin Kim19.79 %19.79%
- Kyung-Sun Kang3.363 %3.36%
- Jung-Ho Choi0.278 %0.28%
- Jong-Chun Na0.2324 %0.23%
- Dong-yeol Lee0.1625 %0.16%
Share of the company, as of September 25, 2026
Leadership
- Jong-Cheon Na — Chief Executive Officer
- Tae-Wha Lee — Senior Vice President and Internal Director, 64
- Kyung-Sun Kang — Founder, 62
- Kwang-Won Seo — Vice President and Internal Director, 59
How much revenue does Kangstem Biotech make?
Kangstem Biotech reported 3.57 billion KRW in revenue for fiscal year 2025, down 53.9% from 7.75 billion KRW in fiscal year 2024. In Q1 2026 revenue was 805.01 million KRW.
What is Kangstem Biotech's largest business segment?
Non-Clinical Trials, with 7.12 billion KRW or 55% of segment revenue in fiscal year 2023. Next: Cosmetics (32%) and Stem Cell (11%).
What companies are similar to Kangstem Biotech?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include curacle co.,ltd. (365270.KQ), DAE HWA Pharmaceutical Co., Ltd. (067080.KQ), Daewon Pharmaceutical Co., Ltd. (003220.KS), Green Cross WellBeing Corporation (234690.KQ).
How has Kangstem Biotech's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 12.40 billion KRW; FY2022, 16.30 billion KRW; FY2023, 12.70 billion KRW; FY2024, 7.75 billion KRW; FY2025, 3.57 billion KRW.
Has Kangstem Biotech made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 21.35 billion KRW; FY2022, a loss of 20.24 billion KRW; FY2023, a loss of 21.95 billion KRW; FY2024, a loss of 7.99 billion KRW; FY2025, a loss of 10.48 billion KRW. It reported a net loss in each of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Kangstem Biotech Co., Ltd. (217730.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/217730.KQ